Long-Term Trend in Pediatric Antidepressant Use, 1983–2007: A Population-Based Study

Xiangfei Meng, PhD1; Carl D’Arcy, PhD2; Raymond Tempier, MD, MSc, FRCP, FCPA3

1Research Fellow, Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan.
Correspondence: Department of Psychiatry, College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK S7N 0W8; xiangfei.meng@usask.ca.
2Professor, Department of Psychiatry and School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan.
3Professor, Department of Psychiatry, Hôpital Montfort, University of Ottawa, Ottawa, Ontario.

Objective: Research is needed to clarify and improve our understanding of appropriateness and safety issues concerning antidepressant (AD) treatment. We explored the long-term trend in the dispensing of pediatric ADs using provincial, population-based data from Canada.

Methods: Data covering 22 ADs were drawn from the Saskatchewan Ministry of Health administrative data files in outpatient settings. The data were for 9 triennial years from 1983 to 2007, a 24-year period, for those aged 0 to 19 in the general population. Descriptive analyses were used.

Results: In 1983, 5.9 per 1000 population aged 0 to 19 were dispensed at least 1 AD; this decreased to 5.1 per 1000 population in 1989, and then increased to 15.4 per 1000 population in 2007, with a slower increase after 2004. Both sexes were dispensed more ADs from 1989 onwards, with females being the heavier users. The rate of AD use increased significantly with age, and this trend became more pronounced after 1998. Family physicians were the major prescribers and their prescriptions significantly increased from 1989 to 2004 and decreased in 2007. The use of selective serotonin reuptake inhibitors (SSRIs) was the major reason for the increase. The number of AD scripts per patient also increased.

Conclusions: The growth in the prevalence of AD use among children and youth was largely caused by the use of SSRIs. The possibility of safety issues induced by AD use among children and adolescents, and different patterns of medication practice, suggest continuing education is warranted.

Tendance à long terme de l’utilisation d’antidépresseurs pédiatriques, de 1983 à 2007 : une étude dans la population

Objectif : La recherche est nécessaire pour clarifier et améliorer notre compréhension des questions d’applicabilité et d’innocuité concernant le traitement aux antidépresseurs (AD). Nous avons exploré la tendance à long terme de la dispensation d’AD pédiatriques à l’aide des données provinciales d’une population du Canada.


Résultats : En 1983, 5,9 par 1000 population âgés de 0 à 19 ans se sont fait dispenser au moins 1 AD, ce qui a diminué à 5,1 par 1000 de population en 1989, puis qui a augmenté à 15,4 par 1000 de population en 2007, l’augmentation étant plus lente après 2004. Plus d’AD ont été dispensés aux deux sexes à compter de 1989 et après, les filles étant les plus grandes utilisatrices. Le taux d’utilisation des AD s’est accru significativement avec l’âge, et cette tendance est devenue plus marquée après 1998. Les médecins de famille étaient les principaux prescripteurs et leurs ordonnances ont augmenté...
Since researchers in the 1950s discovered the first ADs, TCAs, and MAOIs, a wide variety of ADs have become available and commonly prescribed to children and adolescents for depression, anxiety, and other mental disorders. The diversity of ADs allows clinicians to individualize treatment decisions for psychiatric symptoms, as well as to avoid potential side effects. Increased use of ADs for youth has been reported over decades in the United Kingdom, Italy, Denmark, the Netherlands, and the United States. SSRIs have been the major contributor to this upward trend.

Like all medications, ADs warrant concerns in terms of efficacy, tolerability, and safety. Generally, ADs have several side effects, such as weight gain, sexual dysfunction, fatigue, and sleepiness. Consequences of these side effects may adversely impact patients’ compliance and thereby influence outcome, and increase risk of morbidity and mortality. There have been further concerns expressed about the safety issue of ADs in pediatric patients. In 2004, drug regulatory agencies in the United States (Food and Drug Administration), Canada (Health Canada), and the United Kingdom (Medicines and Healthcare Regulatory Agency) released warnings on ADs in pediatric patients, including suicidality, violence, aggression, mania, and other abnormal behavioural changes. Epidemiologic studies on trends of AD use in children and adolescents have been conducted to examine the influence of warnings on the use of ADs. Generally, prescriptions of SSRIs (except fluoxetine, which remained stable) decreased during 2003 to 2005, but increased afterwards. Notably, there has been significant national variability in patterns of psychotropics practice, owing to the introduction of new drugs, controversies over which drugs are better and more effective, different drug regulations, drug safety, cultural meaning of drug treatment in pediatric populations, and each country imprinting its own particular culture.

Recently, Tsapakis et al conducted a systematic review and meta-analysis of randomized controlled trials comparing responses to ADs and placebo in youth with depression. They concluded that most ADs, with the exception of fluoxetine, provided only limited efficacy in adolescent depression. Although clinical trials generally could provide better quality evidence than other study designs, short-term follow-up and small sample size limit the use of clinical trials in exploring trends of using pharmaceuticals. Health policy experts have suggested that existing health record databases should be studied to identify early warnings of adverse side effects of drugs, and to develop evidence-based health policy.

Given the widespread use of ADs, the possibility of suicidality induced by ADs among children and adolescents, and different patterns of medication practice, data on the long-term trend of pediatric AD use in a general population are needed. In our study, we aimed to examine trends in pediatric AD use in general and in population subgroups over a 24-year period in a Canadian provincial population.

**Methods**

**Context**

Provincial governments in Canada take the responsibility of most health services delivered within their provinces. Although the precise range of services may vary by province, these services include almost all hospital and physician services, as well as a significant proportion of nursing home care, prescription drug subsidies, and public health. Saskatchewan is a prairie province, which has a
Results

There were 1814 children and adolescents in Saskatchewan (5.9 per 1000 population of the covered children and adolescents aged 0 to 19) who received at least 1 prescription for ADs in 1983. The overall AD use prevalence rate in this age range decreased to 5.1 per 1000 population in 1989, then gradually increased to 15.4 per 1000 population in 2007. This was a 1.61-fold increase from 1983.

Figure 1a shows trends in numbers of dispensed ADs per 1000 children and adolescents in Saskatchewan from 1983 to 2007 (24 years). The number of dispensed AD prescriptions was 4156 in 1983, and it significantly increased to 19 715 in 2007. The rate of dispensed ADs among children and adolescents was 13.43 per 1000 in 1983, decreased to 12.27 per 1000 in 1989, and gradually increased to 79.29 per 1000 in 2007. Figure 1b presents standardized rates of dispensed ADs for different age groups. It shows that

1) the rate of AD use significantly increased among those aged 10 to 14 and aged 15 to 19;
2) this increasing trend became more pronounced during the 1998 to 2007 period;
3) the rate of ADs dispensed to those aged 5 to 9 fluctuated during the study period, and consistently decreased after 2001; and,
4) there was a decrease in the rate of dispensed ADs among those aged less than 5 years old.

Compared with males, females received fewer ADs in 1983 and 1986. Both sexes used more ADs from 1989 onwards, and females were the heavier AD users. Adolescents aged 15 to 19 years were the major age group of AD users, and their use increased substantially from 1998 onwards. There were consistent increasing trends in use for adolescents aged 15 to 19 and those aged 10 to 14 in both males and females. Notably, the use of ADs decreased during 2004 to 2007 for children aged 5 to 9 (Figure 2a and 2b).

Family physicians were the major prescribers, and their prescriptions significantly increased from 1989 to 2004 and decreased in 2007. Psychiatrists were the second major group, and their prescriptions consistently increased over the 24-year study period. The rate of dispensed ADs prescribed by other medical specialties also slightly increased. The rate of ADs prescribed by noncertified psychiatrists (physicians with psychiatric training, but who have not completed examinations for certification and who are allowed to practice with a specific license) significantly increased in 1998 and remained at a higher level afterwards, compared with 1983 (Figure 3).

The use rate of SSRIs significantly increased since their introduction. Again, the rate of other AD use also rose, but had slightly decreased in 2007. In contrast, the MAOIs dispensing rate remained constant at a very low level. More fluctuations were observed in the rate of TCAs. Both TCAs and other ADs experienced a decrease in use after 2004. There was a dramatically decreasing trend in the usage of TCAs for children aged younger than 9 years old. Conversely, adolescents aged 15 to 19 were dispensed...
an increasing number of TCAs during the study period. In general, females were dispensed more TCAs over time (Figure 4).

Figure 5 shows percentages of pediatric patients who were dispensed different numbers of ADs during the study period. There was an increasing trend in the percentage of those having 7 or more ADs dispensed per year, whereas a decreasing trend was observed in the percentage of those who were dispensed a single AD in a given year. The percentage having 2 to 6 prescriptions per year fluctuated over the 24-year period. Children and adolescent patients were dispensed more ADs per year over time regardless of sex. The percentages of dispensed ADs used by adolescents aged 15 to 19 dramatically increased in all prescription groups. Notably, the percentage of single prescriptions per year consistently and significantly decreased for both males and females. The percentages of only 1 AD per year dramatically decreased over time in all age groups (except adolescents aged 15 to 19). Family physicians were the
major group to prescribe single ADs annually to pediatric patients, but their role had decreased over time. In contrast, the percentage of single ADs prescribed by noncertified psychiatrists was on the rise over the study period.

**Discussion**

In 1983, 5.9 per 1000 population aged 0 to 19 were dispensed at least 1 AD prescription, this decreased to 5.1 per 1000 in 1989, and then increased to 15.4 per 1000 in 2007, with a slower increase after 2004. Both sexes received more ADs from 1989 onwards, with females being the heavier users. The rate of AD use significantly increased with age, and this trend became more pronounced after 1998. Family physicians were the major prescribers and their prescriptions significantly increased from 1989 to 2004 and decreased slightly at 2007. The use of SSRIs was the major reason for this increase. Pediatric AD use became more frequent, as an increase in the percentage of patients with 7 or more prescriptions per year, whereas the percentage of 1 AD prescription dispensed per year decreased.
Evidence shows that mental disorders, especially depression, are being more frequently diagnosed among children and adolescents. Epidemiologic studies have found that mood and anxiety disorders are the most common psychiatric disorders in children and adolescents, and are likely to be chronic and increase vulnerability to other diseases. A population-based study on children and adolescents had shown that those who were growing up in the 1990s had a 1 in 6 chance of getting a psychiatric disorder and the rate increased to 1 in 3 by the age of 16.

Costello et al systematically conducted a meta-analytic study on the prevalence of depression between 1965 and 1996, and found that the prevalence of depression was 2.8% for those aged under 13, 5.9% for girls aged between 13 to 18, and 4.6% for boys aged 13 to 18. O’Neil et al in their review suggest that community and clinical studies have shown that a range of 9.0% to 47.9% of adolescents had comorbidity between internalizing disorders and substance use. Recently, Merikangas et al reviewed the magnitude of mental disorders in children and adolescents; despite
The safety issue of ADs in children and adolescents has been studied, but the efficacy of these drugs in juvenile depression has not been explicitly studied. More importantly, although CBT has been widely seen as an evidence-based treatment in children and adolescents, and has been considered as the most appropriate treatment for those who suffer from mild mental disorders, pharmacotherapy, and in particular ADs, may be an alternative or adjunct to CBT for more severe cases.

Consistent with studies conducted in Quebec, Taiwan, the United States, the trend of AD use in children and adolescents has increased since the late 1990s. This trend was mainly a result of the increased use of SSRIs and other ADs. Our study found that the rate of pediatric use of ADs in Saskatchewan was 5.9 per 1000 in 1983, decreased in 1989, and then increased to 15.4 per 1000 in 2007. Pediatric AD use of children and adolescents in Taiwan increased during 1997 to 2005 from 2.7 per 1000 to 4.7 per 1000. The US rates increased from 13 per 1000 in 1997 to 18 per 1000 in 2002. Caution has to be paid when comparing the rate of pediatric AD use among studies for 3 reasons: studies were conducted at different time periods; characteristics of subjects varied by study; and insurance coverage of ADs differed.

Regulatory warnings resulted in a temporal decline in pediatric AD use during 2003 to 2005, but the use of ADs rebounded afterwards. This phenomenon could be explained by the following: clinicians were influenced by regulatory warnings in terms of making psychiatric diagnosis and offering prescriptions, and further studies on safety issues of ADs did not find evidence to support suicidal and violent acts as induced by ADs in youth, the influence of those warnings on clinicians was short-term. Our study found that a slower increase of pediatric AD use after 2004, which is in line with the trends in SSRI use in pediatric patients reported by a Quebec study and a Taiwanese study, and a decrease in the rate of ADs dispensed by family physicians after 2004, which may indicate that they were influenced by the warnings.

Our study also observed the prevalence of pediatric AD use increased with age. The increasing trend in use from 1983 to 2007 was most pronounced in the adolescent group (aged 15 to 19), and their use getting more frequent; this is also true for other studies. Adolescents are more likely to be judged to suffer with depression, anxiety, and other psychological difficulties, compared with children. The substantial increasing use of SSRIs is consistent with an increasing number of adolescent psychiatric patients. Females were more likely to use ADs in our study. Inconsistent findings on the role of sex in pediatric AD use have been reported. The discrepancy may be explained by the prevalence of psychiatric disorders varying between the sexes at different ages, and by structural differences in the proportions of males and females at different ages across studies.

Notably, the use of TCAs remained fairly constant over the study period. There was a dramatically decreasing trend in the usage of TCAs for those aged younger than 9 years. Conversely, adolescents aged 15 to 19 were dispensed an increasing number of TCAs. In addition, our study found that TCA use was more frequent in adolescents. It was
likely that TCAs were used to treat psychiatric problems in this age group. Though one might consider TCAs prescribed for physical problems, such as bedwetting, we found a dramatically decreasing trend in the usage of TCAs for those aged younger than 9 years.

Family physicians played the major role in AD prescribing, followed by psychiatrists. However, there was a decrease in the prescription rate of ADs by family physicians after 2004. This phenomenon may be explained by the following: family physicians may be more influenced by the regulatory warnings; or the prescribing of ADs in children and adolescents shifted from generalists to psychiatric specialists, as we observed the rate of ADs dispensed by psychiatrists consistently increased during the 24-year period. The number of AD prescriptions dispensed per patient also increased, which parallels findings from the United States.

Several findings from our comparison of AD use across subgroups warrant further attention. First, the effectiveness and appropriateness of frequently used ADs should be examined. Second, family physicians played a major role in AD prescriptions; therefore, continuing training and education on their use of ADs should be reinforced. Third, given the dramatic increase of SSRI use, research should be strengthened on the effectiveness and safety of individual SSRIs, and should help to identify the relative safety and balance of risks for pediatric patients.

Our study has some limitations. First, the range of variables in the data analyzed limits our ability to explore roles of other variables that may influence use. Second, data only had categorical information on the subclasses of ADs, data on specific ADs were not retrieved. Third, since our study only had one study point after 2004, the trend of pediatric AD use after regulatory warning needs to be reexamined with further post-2004 data.

Conclusions

Saskatchewan experienced an increasing trend in pediatric AD use from 1983 to 2007. The use of SSRIs significantly contributed to the trend. Family physicians and psychiatrists were the major prescribers. AD use increased with age, and the number of prescriptions per patient became more frequent. Given the use of ADs had dramatically increased, the possibility of safety issues induced by AD use among children and adolescents, and different patterns of medication practice, continuing education is warranted.

Acknowledgements

Dr Meng was funded by the Saskatchewan Research Foundation as a postdoctoral fellow. A Canadian Foundation for Innovation Leaders Opportunity Foundation Award (16995) was used to offset the costs involved in acquiring the data analyzed in the study.

Our study is based, in part, on de-identified data provided by the Saskatchewan Ministry of Health. The interpretations and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Ministry of Health.

References

Long-Term Trend in Pediatric Antidepressant Use, 1983–2007: A Population-Based Study

28. Cincinnati Children’s Hospital Medical Center. Treatment of children and adolescents with major depressive disorder (MDD) during the acute phase. Cincinnati (OH): Cincinnati Children’s Hospital Medical Center; 2010.